CVRS Corindus Vascular Robotics Inc

[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Long David W	2. Issuer Name and Ticker or Trading Symbol Corindus Vascular Robotics, Inc. [ CVRS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) CFO/Sr VP/Sec./Treasurer
(Last)          (First)          (Middle) 309 WAVERLEY OAKS RD., SUITE 105	3. Date of Earliest Transaction (MM/DD/YYYY) 10/29/2019
(Street) WALTHAM, MA 02452 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified stock option (right to buy)	$0.5499	10/29/2019		D (1)			590048	(2)	9/4/2021	Common Stock	590048	$3.73 (3)	0	D
Non-qualified stock option (right to buy)	$0.7507	10/29/2019		D (1)			285773	(4)	6/4/2024	Common Stock	285773	$3.5293 (3)	0	D
Non-qualified stock option (right to buy)	$1.46	10/29/2019		D (1)			100000	(5)	6/22/2026	Common Stock	100000	$2.82 (3)	0	D
Non-qualified stock option (right to buy)	$1.17	10/29/2019		D (1)			100000	(6)	4/6/2027	Common Stock	100000	$3.11 (3)	0	D
Non-qualified stock option (right to buy)	$1.05	10/29/2019		D (1)			110000	(7)	2/1/2028	Common Stock	110000	$3.23 (3)	0	D
Non-qualified stock option (right to buy)	$1.2	10/29/2019		D (1)			110000	(8)	1/31/2029	Common Stock	110000	$3.08 (3)	0	D

Explanation of Responses:
(1)	On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
(2)	This option provided for vesting over a period of four years, with the first 25% vesting on September 5, 2012 and the remaining 75% vesting in 36 equal monthly installments at the end of every month thereafter.
(3)	At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes.
(4)	This option provided for vesting over a period of four years, with the first 25% vesting on June 5, 2015 and the remaining 75% vesting in 36 equal monthly installments at the end of every month thereafter.
(5)	This option provided for vesting over a period of four years, with the first 25% vesting on June 23, 2017 and the remaining 75% vesting in 36 equal monthly installments at the end of every month thereafter.
(6)	This option provided for vesting over a period of four years, with the first 25% vesting on April 7, 2018 and the remaining 75% vesting in 36 equal monthly installments at the end of every month thereafter.
(7)	This option provided for vesting over a period of four years, with the first 25% vesting on February 2, 2019 and the remaining 75% vesting in 36 equal monthly installments at the end of every month thereafter.
(8)	This option provided for vesting over a period of four years, with the first 25% vesting on February 1, 2020 and the remaining 75% vesting in 36 equal monthly installments at the end of every month thereafter.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Long David W 309 WAVERLEY OAKS RD., SUITE 105 WALTHAM, MA 02452			CFO/Sr VP/Sec./Treasurer

Signatures
/s/ David W. Long		10/31/2019
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.